AI Article Synopsis

  • The study looks at how different ways to define aggressive prostate cancer (PCan) can help find communities where men might need help with this cancer.
  • Researchers used data from Pennsylvania to see how different definitions change the number and locations of cases identified.
  • They found that one specific definition (D2) was the best for matching areas with higher death rates from prostate cancer and might help scientists do better studies in the future.

Article Abstract

Background: Spatial analysis can identify communities where men are at risk for aggressive prostate cancer (PCan) and need intervention. However, there are several definitions for aggressive PCan. In this study, we evaluate geospatial patterns of 3 different aggressive PCan definitions in relation to PCan-specific mortality and provide methodologic and practical insights into how each definition may affect intervention targets.

Methods: Using the Pennsylvania State Cancer Registry data (2005-2015), we used 3 definitions to assign "aggressive" status to patients diagnosed with PCan. Definition one (D1, recently recommended as the primary definition, given high correlation with PCan death) was based on staging criteria T4/N1/M1 or Gleason score ≥ 8. Definition two (D2, most frequently-used definition in geospatial studies) included distant SEER summary stage. Definition three (D3) included Gleason score ≥ 7 only. Using Bayesian spatial models, we identified geographic clusters of elevated odds ratios for aggressive PCan (binomial model) for each definition and compared overlap between those clusters to clusters of elevated hazard ratios for PCan-specific mortality (Cox regression).

Results: The number of "aggressive" PCan cases varied by definition, and influenced quantity, location, and extent/size of geographic clusters in binomial models. While spatial patterns overlapped across all three definitions, using D2 in binomial models provided results most akin to PCan-specific mortality clusters as identified through Cox regression. This approach resulted in fewer clusters for targeted intervention and less sensitive to missing data compared to definitions that rely on clinical TNM staging.

Conclusions: Using D2, based on distant SEER summary stage, in future research may facilitate consistency and allow for standardized comparison across geospatial studies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424402PMC
http://dx.doi.org/10.1186/s12885-023-11281-8DOI Listing

Publication Analysis

Top Keywords

aggressive pcan
12
pcan-specific mortality
12
aggressive prostate
8
prostate cancer
8
definition
8
geospatial studies
8
distant seer
8
seer summary
8
summary stage
8
geographic clusters
8

Similar Publications

Keratin 17 modulates the immune topography of pancreatic cancer.

J Transl Med

May 2024

Department of Pathology, Renaissance School of Medicine, Stony Brook University, 101 Nicolls Road, Stony Brook, NY, 11794, USA.

Background: The immune microenvironment impacts tumor growth, invasion, metastasis, and patient survival and may provide opportunities for therapeutic intervention in pancreatic ductal adenocarcinoma (PDAC). Although never studied as a potential modulator of the immune response in most cancers, Keratin 17 (K17), a biomarker of the most aggressive (basal) molecular subtype of PDAC, is intimately involved in the histogenesis of the immune response in psoriasis, basal cell carcinoma, and cervical squamous cell carcinoma. Thus, we hypothesized that K17 expression could also impact the immune cell response in PDAC, and that uncovering this relationship could provide insight to guide the development of immunotherapeutic opportunities to extend patient survival.

View Article and Find Full Text PDF
Article Synopsis
  • The study looks at how different ways to define aggressive prostate cancer (PCan) can help find communities where men might need help with this cancer.
  • Researchers used data from Pennsylvania to see how different definitions change the number and locations of cases identified.
  • They found that one specific definition (D2) was the best for matching areas with higher death rates from prostate cancer and might help scientists do better studies in the future.
View Article and Find Full Text PDF

Pre-Diagnosis Pain in Patients With Pancreatic Cancer Signals the Need for Aggressive Symptom Management.

Oncologist

December 2023

Scientific and Medical Affairs, Pancreatic Cancer Action Network (PanCAN), Manhattan Beach, CA, USA.

Objective: This study assessed the impact of pancreatic cancer (PC) pain on associated symptoms, activities, and resource utilization from 2016 to 2020 in an online patient registry.

Patients And Methods: Responses from PC patient volunteers (N = 1978) were analyzed from online surveys in a cross-sectional study. Comparisons were performed between PC patient groups reporting, (1) the presence vs.

View Article and Find Full Text PDF
Article Synopsis
  • The study categorized pancreatic ductal adenocarcinoma (PDAC) using imaging techniques based on qualitative (high or low delta) assessments of tumors observed in CT scans.
  • A new quantitative classification method (q-delta) was developed, showing that low q-delta tumors consistently correlate with better patient outcomes and survival rates compared to high q-delta tumors.
  • The findings indicate that this q-delta classification could serve as a valuable tool in clinical settings and may enhance the design of future clinical trials for PDAC.
View Article and Find Full Text PDF

Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer-related deaths in the United States by 2020, due in part to innate resistance to widely used chemotherapeutic agents and limited knowledge about key molecular factors that drive tumor aggression. We previously reported a novel negative prognostic biomarker, keratin 17 (K17), whose overexpression in cancer results in shortened patient survival. In this study, we aimed to determine the predictive value of K17 and explore the therapeutic vulnerability in K17-expressing PDAC, using an unbiased high-throughput drug screen.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!